Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of tumour dynamics over a 6-week course of concurrent chemoradiotherapy for glioblastoma and the impact on survival.
Ong WL, Stewart J, Sahgal A, Soliman H, Tseng CL, Detsky J, Chen H, Ho L, Das S, Maralani P, Lipsman N, Stanisz G, Perry J, Lim-Fat MJ, Atenafu EG, Lau A, Ruschin M, Myrehaug S. Ong WL, et al. Among authors: tseng cl. Int J Radiat Oncol Biol Phys. 2024 Mar 30:S0360-3016(24)00453-X. doi: 10.1016/j.ijrobp.2024.03.036. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38561051 Free article.
Stereotactic Body Radiation Therapy for Sacral Metastases: Deviation From Recommended Target Volume Delineation Increases the Risk of Local Failure.
Moore-Palhares D, Zeng KL, Tseng CL, Chen H, Myrehaug S, Soliman H, Maralani P, Larouche J, Shakil H, Jerzak K, Ruschin M, Zhang B, Atenafu EG, Sahgal A, Detsky J. Moore-Palhares D, et al. Among authors: tseng cl. Int J Radiat Oncol Biol Phys. 2024 Feb 22:S0360-3016(24)00282-7. doi: 10.1016/j.ijrobp.2024.01.213. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38395085 Free article.
Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT).
Glicksman RM, Loblaw A, Morton G, Vesprini D, Szumacher E, Chung HT, Chu W, Liu SK, Tseng CL, Correa R, Deabreu A, Mamedov A, Zhang L, Cheung P. Glicksman RM, et al. Among authors: tseng cl. Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):100-109. doi: 10.1016/j.ijrobp.2023.11.006. Epub 2023 Nov 17. Int J Radiat Oncol Biol Phys. 2024. PMID: 37979707 Clinical Trial.
308 results